Market Overview

The Global Infectious Vaccines Market in terms of revenue was estimated to be worth USD 91.45 Billion in 2023 and is poised to reach USD 172.27 Billion by 2032, growing at a CAGR of 7.3% from 2024 to 2032.

The infectious vaccines market is the global industry that researches, develops, manufactures, and distributes vaccinations intended to prevent infectious diseases brought on by bacteria and viruses. This market improves global health by reducing the incidence and spread of a variety of infectious diseases through the inclusion of a wide range of vaccine types.

Some of the vaccines available for purchase are intended to treat infections that arise due to such infectious agents as bacteria and viruses and other infectious-causing agents. Viral vaccines, because they suppress the outbreaks of infectious agents, decrease the rate at which patients die and, generally save the world from further spending in the healthcare sector are highly valued in times like COVID-19 pandemics and epidemics. Such immunizations will benefit not only the end-users like hospitals, clinics, and the health organizations of the government, but the various applications include different kinds of people and medical environments. Several factors are seriously affecting the market, which are connected with the rise of infectious diseases, funding through governments, biotechnologies discovered, and improvement in the infrastructure for health care, and raising consciousness among people toward the preventative health care facility. In a recent trend associated with vaccine research through the help of mRNA and vector-based technology, the pharmaceutical business can create a rapid vaccine solution that will come as more flexible.

Affordable vaccines in developing countries represent a massive potential market. Several challenges may face the growth of the market, for instance, high R&D costs, strict regulatory frameworks, and ethical issues with the procedures of trial. The access is even harder with logistics problems in vaccination distribution in resource-poor environments. Continued research into vaccines for neglected and emerging diseases, as well as heat-stable vaccines that do not require cold-chain logistics, can be very revolutionary in terms of fostering innovation and making it easier to expand in the market. The mutual efforts of governments and biotechnology companies can assist in moving the concept of universal immunization closer to reality while promoting a conducive environment for enhancing public health. The firm must stay updated with regulatory changes and make big investments in data-driven strategies for reaping the benefits of bio similar and bio superior vaccine markets, mainly dependent on regional infectious disease profiles and healthcare demands.

These markets present exciting and challenging opportunities to industry stakeholders. Examining such opportunities with minimal drawbacks may foster long-term growth in a technologically competitive and evolving market.

Key Findings

• In order to improve childhood vaccination, UNICEF and the Azerbaijani Ministry of Health extended their partnership in February 2024.
• In February 2024, the Africa CDC and UNICEF extended their partnership to improve primary healthcare, supply chain management, and childhood vaccinations in Africa.
• Bharat Biotech and Bilthoven Biologicals B.V. partnered in April 2024 to manufacture and distribute oral polio vaccinations.
• In order to expedite the development of its unique MLE platform, enveloped virus-like particle vaccine technology that permits the coding of eVLPs using mRNA, VBI Vaccines Inc. extended its strategic partnership with the Canadian government in April 2024.
• Indian Immunologicals Ltd. (IIL) introduced Havisure, the country's "first" domestically produced Hepatitis A vaccine, in January 2024.
• Affinivax, Inc., a clinical-stage biopharmaceutical business specializing on creating innovative next-generation pneumococcal vaccines, was purchased by GSK in August 2022. The company wants to expand its product line with this acquisition.
• The Indonesia National Agency for Drug and Food Control approved Takeda Pharmaceutical Company Limited's dengue tetravalent vaccine, QDenga, for use in people aged six to forty-five in August 2022.
• In July 2022, the European Union approved Imvanex, a product of Danish biotechnology company Bavarian Nordic, to prevent monkeypox.
• The next-generation glass Prefillable Syringe (PFS), created in partnership with top pharmaceutical firms to address the intricate and changing requirements of vaccine manufacture, was introduced by BD in September 2022.

Market Dynamics - Market Drivers

Public Health Initiatives and Government Support

Vaccination campaigns that are backed by the government are instrumental in improving vaccination rates while keeping outbreaks of infectious diseases under control. Most these programs are quite comprehensive when it comes to public health measures implemented with specific populations in focus, such as children and elderly, along with medically challenged people. In the process, a government, for example, may increase mass vaccinations through very low, almost free-of-cost vaccinations. In addition, public awareness campaigns that educate the public on the importance and safety of vaccinations usually accompany the activities, which contribute to the battle against vaccine hesitancy and misinformation.

The infectious vaccine market is expanding owing to favourable public health policies in addition to increased financing toward the research and development on the vaccine. Governments, amongst other international organizations, highly fund the development of novel vaccines especially regarding emerging infectious diseases. Such policies as school or job entrance requirements for health facilities stress the importance of vaccination among the public and, at the same time, add weight to this public health intervention. All these practices, together, create an impressive framework that makes systems generally stronger in countering any infectious disease threat while advocating vaccination uptake.

Key Findings

• Researchers at the University of Buffalo in the United States used nano-liposome technology to create a promising recombinant flu vaccine in February 2024.
• Chinese vaccine developer Maxvax Biotechnology raised USD 82.5 million in Series C funding in July 2024.
• co-exclusive licensing deal to co-commercialize a COVID-19 vaccine and work together to create innovative COVID-19 and influenza combo vaccines was revealed by Novavax and Sanofi in May 2024. Through this strategic alliance, both businesses can use their resources and areas of expertise to develop and sell novel vaccination solutions. Sanofi and Novavax hope to strengthen their competitive position in the quickly changing vaccine development and distribution market by partnering. The deal represents a proactive strategy to address public health issues and satisfy the growing need for efficient vaccines to prevent infectious diseases.

Market Opportunities

Collaborative Research and Development

Public-private partnerships (PPPs) are an essential factor that will move cooperation between governments, pharmaceutical corporations, and NGOs in terms of making vaccines quicker. It joins the creative forces and effectiveness of the private sector with government strengths in a combination through the proper usage of resources and regulation, maximized to each respective side. By streamlining procedures for the production of vaccines, sharing research expenses with each other, and perfecting logistical skills in order to deliver vaccines, stakeholders could ensure that vaccines reached all populations that needed them, but especially those in low-and middle-income countries.

Companies have a lot of options to participate in global health programs such as the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi (the Vaccine Alliance). These programs often prioritize access in underprivileged areas in treating infectious disease outbreaks and raising immunization rates worldwide. Cooperation by the groups enables businesses to access finance and resources, which increases an entry to new markets for sales while coordinating vaccine research works as that relates to global health. Cooperative strategy enhances both rank and spread of the engaged business entities and also mitigates the fight against emergencies brought by public health, with positive implications on health care all over the world eventually.

Key Findings:

• The U.S. FDA authorized Ixchiq, the first chikungunya vaccine, in November 2023 to prevent illness brought on by the chikungunya virus.
• The US FDA approved GSK plc's adjuvanted respiratory syncytial virus vaccine, Arexvy, in May 2023 for the prevention of respiratory syncytial virus (RSV)-induced lower respiratory tract disease (LRTD) in people 60 years of age and older.
• In January 2023, Bharat Biotech introduced iNCOVAC, an in-house nasal COVID-19 vaccination for adults over 18.

Market Restraining Factors

Limited Access in Developing Regions

Infrastructure problems, particularly in low- and middle-income settings, significantly affect the delivery and distribution of vaccination. Many places have poor health-care facilities, poor transport systems, and limited capacity to store vaccines-which, by the way, are highly sensitive to temperature control. This lack of infrastructure could lead to delayed delivery of vaccines, increased rates of spoilage, and lower immunization coverage in the end. Logistical constraints might make it difficult to reach the vulnerable populations of rural or remote areas, worsening access to health care.

The main constraint to accessing vaccines is the financial factors. Developing, making, and distributing vaccines are very costly and hence expensive for some countries with low incomes. Such regions may have strapped governments which cannot afford to set aside money for vaccination campaigns or may not have the ability to fund vaccines at a reasonable cost. It results in reliance on foreign donations and aid, which are never to be relied upon or prove to be insufficient for fulfilling public health needs. Consequently, targeted investments and creative avenues to improve affordability and infrastructure in low-income areas have great importance since people who live in these areas tend to be more vulnerable to infectious diseases.

Segmentation Analysis

The market scope is segmented because of by Vaccine Type, by Administration Route, by Disease Target.

By Vaccine Type

Based on the Vaccine Type of the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines, mRNA Vaccines, Vector Vaccines.

The majority of the Infectious Vaccines Market is live attenuated vaccines, which are the weakened forms of pathogens. They cause a strong and long-lasting immune response in the body. Examples of these vaccines include the measles, mumps, and rubella (MMR) vaccine. These vaccines work since they replicate natural infections; hence, they trigger the body to produce strong immunity. Inactivated vaccines consist of killed pathogens and hence are safer but sometimes a series of doses may require eliciting adequate immunity, such as the vaccine for hepatitis A and polio. Subunit, recombinant, and conjugate vaccines focus only on specific parts of the pathogen and thus are safer and more effective for a whole host of diseases, for example, the HPV vaccine and pneumococcal vaccine.

The mRNA vaccines, a new technology exemplified by the COVID-19 vaccines, work on messenger RNA to instruct cells to produce a protein similar to that of the pathogen, which then triggers an immune response without using live virus. Vector vaccines, as exemplified by Ebola vaccines, use a harmless virus to deliver genetic material from the target pathogen. All these types play important roles in combating infectious diseases.

By Administration Route

Based on the Administration Route of the market is segmented into Intramuscular (IM),Subcutaneous (SC),Oral Vaccines, Intranasal Vaccines.

Different routes of vaccine administration are available, and specific settings have one route as a better alternative than another. IM injections are the most commonly used because vaccines injected into the muscle are absorbed rapidly and induce an intense immune response. Intramuscular injections are very common in vaccines such as hepatitis B and COVID-19.Subcutaneous refers to the process of injecting the vaccine under the skin. This mode of administration is mostly used for vaccines such as MMR: measles, mumps, and rubella. It is easily and efficiently administered without needing a deep muscle injection. Oral vaccines can be administered orally, which facilitates mass immunization. This route is more favourable in developing countries because it does not require sterile equipment nor trained health care professionals for injection. The rotavirus vaccine, for example, reduces severe diarrhoea in young children. Third, an intranasal vaccine that is administered through the passage of the nose is entirely injection-free. Some flu vaccinations are a great example that provides a way of increasing ease of acceptability and compliances to vaccination, especially given to individuals who fear use of needles. Every route into the administration is vital as it aids in optimizing vaccinating efforts.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America holds a significant place for vaccine manufacturers, mainly because its healthcare systems are of highly developed standards, along with investments in research and development being considerably high, and also there being a well-structured framework of regulation. Significant players for the region include the United States and Canada. Their vaccination programs are significantly driven by government initiatives. It includes the Vaccines for Children Program. Such factors make it a paradise of innovation, allowing big pharm and research centres to quickly develop and then fast-track new vaccines through to approval. High public awareness of the vaccination benefits also promotes this region's market growth.

Regulatory support is highly observed in the Europe region along with well-established vaccination programs. Germany, France, and the UK are a few countries that have proper immunization schedules. All such efforts are funded by governments as well as health care initiatives. The EMA works to ensure safety and effectiveness of vaccines in order to gain the trust of people. However, the region still feels the challenges of vaccine hesitation, which has set the campaigns to educate the public to upsurge vaccination rates mostly concerning childhood immunizations.

One of the fastest-growing infectious vaccines markets is the Asia-Pacific region, which arises as a result of growth in health care expenditure and raising awareness about the advantage of vaccination, and with it, the burden of infectious diseases is growing. India and China are investing considerably in vaccine development and manufacturing capacity, both to satisfy their national needs and global health requirements. Public-private partnerships are also gaining momentum, thereby granting access to vaccines in areas where they are so sorely needed. Initiatives such as Gavi also provide an important tool to increase the accessibility of vaccines in low-income countries of this region to expand market opportunities.

Latin America provides a mixed view of the infectious vaccines market. For instance, Brazil and Mexico have developed immunization programs. However, other challenges like economic inequality and access to healthcare services impede proper immunization efforts. There is increased collaboration between governments and international organizations in the region in the aim of strengthening immunization efforts in response to outbreaks of preventable diseases.

This market here, Middle East and Africa, presents rather massive challenges, most fundamentally attributed to low health infrastructures, political instabilities, and economic boundaries. However, it's improving here, especially considering that global health institutions and governments are acting towards improvements, which help expand the coverage on vaccination. Improvements on the cold chain logistics will pave a way forward by reaching people or creating awareness of people towards the vaccine, therefore providing ways for growth.

Regional factors characterize the infectious vaccines market. Each region makes the overall global vaccination land scenario challenging and provides the vaccine market with opportunities in a certain region.

List of Companies Profiled

• Abbott Laboratories
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Bavarian Nordic A/S
• Bharat Biotech
• Biological E Ltd.
• CSL Limited
• DAIICHI SANKYO COMPANY, LIMITED
• Emergent BioSolutions Inc.
• GlaxoSmithKline PLC
• Incepta Vaccine, Ltd.
• Johnson and Johnson Services Inc.
• Lonza Group AG
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis International AG
• Novavax, Inc.
• Pfizer, Inc.
• Sanofi SA
• Serum Institute of India Pvt., Ltd
• Sinovac Biotech Ltd.

Key Industry Developments

• Pfizer released data from phase 3 studies of their RSV vaccines in April 2023. The adult patient study showed that the vaccination was 86% effective in cases of severe illness and 67% more effective in preventing infections with two linked symptoms. This vaccine will be the first medicine on the RSV market if it is approved.
• In order to create cutting-edge vaccines with game-changing technologies like next-generation mRNA, CSL Limited opened a new vaccine research and development center in Waltham, Massachusetts, in March 2023.
• The US FDA approved Pfizer Inc.'s ABRYSVO (Respiratory Syncytial Virus Vaccine) in August 2023. It is intended to prevent LRTD and severe LRTD caused by RSV in infants from birth to six months of age by actively immunizing pregnant women between 32 and 36 weeks of gestation.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Infectious Vaccines Market. The qualitative data includes latest trends, market player’s analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations:

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Infectious Vaccines market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Infectious Vaccines. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Infectious Vaccines companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Infectious Vaccines Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Infectious Vaccines Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Infectious Vaccines Market valued?
• Which region has the largest share in 2024 for the global Infectious Vaccines Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Infectious Vaccines Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: